Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Gilead Sciences
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 4 ans
This study will test an experimental drug called GS-9883/emtricitabine/tenofovir alafenamide (GS-9883/F/TAF) for the treatment of HIV-1 infection The purpose of this study is to test the effectiveness of switching to GS-9883/F/TAF versus continuing on a regimen containing boosted atazanavir (ATV) or darunavir (DRV) plus either emtricitabine/tenofovir (FTC/TDF) or abacavir/lamivudine (ABC/3TC) in virologically suppressed HIV-1 infected adult subjects (HIV-1 RNA < 50 copies/mL)
To evaluate the efficacy of switching to a FDC of GS-9883/F/TAF versus continuing on a regimen consisting of boosted atazanavir or darunavir plus either FTC/TDF or ABC/3TC in HIV-1 infected adult subj...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years and 75 years
Gilead Sciences
Update Il y a 4 ans
Etude GS-US-406-1840 : étude de phase 2, randomisée, multicentrique et en double aveugle visant à comparer l'efficacité et la tolérance de l'entosplétinib, en association avec des corticoïdes à un placebo en association avec des corticoïdes, en traitement de première ligne de patients ayant la maladie du greffon contre l’hôte (GVH) chronique. [essai clos aux inclusions]
La maladie du greffon contre l'hôte (GVH) chronique touche les receveurs d'allogreffe de cellules souches hématopoïétiques lorsque le nouveau système immunitaire est reconstitué sans tolérer complètem...
Country
France
organs
Tout Cancer
Specialty
Soins de Support
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 4 ans
A study with Ledipasvir/Sofosbuvir for adolecents and children with chronic Hepatitis C infection
The primary objective of the PK Lead-in Phase of this study is: - To evaluate the steady state pharmacokinetics (PK) and confirm the dose of LDV/SOF FDC in chronic HCV-infected pediatric subjects The...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Gilead Sciences
Update Il y a 4 ans
Étude GS-US-352-1214 : étude de phase 3, randomisée comparant l’efficacité du momelotinib par rapport au meilleur traitement disponible, chez des patients anémiques ou thrombopéniques ayant une myélofibrose primitive (MEP), ou une myélofibrose post-polyglobulie de Vaquez (MF post-PV), ou une myélofibrose post-thrombocythémie essentielle (MF PTE), traités antérieurement par ruxolitinib. [essai clos aux inclusions]
L’objectif de cette étude est de comparer l’efficacité du momelotinib par rapport au meilleur traitement disponible, chez des patients anémiques ou thrombopéniques ayant une myélofibrose primitive (ME...
Country
France
organs
Sang Hématologie - Autres
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 4 ans
A study evaluating the safety and efficacy of the combination of GS-4059 and Entospletinib with and without obinutuzumab in subjects with chronic lymphocytic leukemia
To determine the preliminary efficacy of finite therapy with the combination of GS-4059 and entospletinib with and without obinutuzumab in subjects with relapsed or refractory chronic lymphocytic leuk...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Gilead Sciences Limited
Update Il y a 4 ans
A Phase 4, Open Label, Randomized, Controlled Study to Assess the Effect on Lipid Profile of Switching from a Stable HAART Regimen of fixed dose Abacavir/Lamivuidine (Kivexa) Plus Efavirenz, to Once Daily Atripla in Adult HIV-1 Infected Subjects With Raised Cholesterol
To determine if switching from a stable HAART regimen of Kivexa + EFV to once daily Atripla leads to a reduction in total fasting cholesterol at 12 weeks.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 4 ans
A Phase 2b, Double blind, Randomized, Parallel Group, Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of GS 9450 in Adults with Chronic Hepatitis C Virus Infection
To compare the efficacy of two oral doses of GS 9450 to placebo in subjects with chronic HCV infection as evidenced by histologic response (at least a 2-point decrease in Knodell necroinflammatory sco...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 4 ans
The purpose of this study is to test the effectiveness and safety of GS-6624 at different dose levels when it is given with Gemcitabine. We want to find out what effects, good and/or bad, GS-6624 has on you and your metastatic pancreatic adenocarcinoma when it is given with Gemcitabine. Gemcitabine is approved by the FDA for metastatic pancreatic adenocarcinoma
To compare the additive efficacy of GS-6624 vs. placebo in combination with gemcitabine as measured by improvement in progression free survival (PFS)
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Gilead Sciences Incorporated
Update Il y a 4 ans
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Comparing 24 or 48 Weeks of GS-9190, in Combination with Peginterferon Alfa 2a and Ribavirin, to 48 Weeks of Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic Hepatitis C Virus (HCV) Infection
To compare the early antiviral activity (complete early virologic response rate; cEVR) of GS-9190 versus placebo, in combination with peginterferon alfa 2a (PEG) and ribavirin (RIBA), following 12 wee...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 4 ans
A trial investigating the safety and efficacy of a drug combination Sofosbuvir/Velpatasvir/GS-9857 for subjects with hepatitis C
To determine the efficacy of treatment with sofosbuvir (SOF)/velpatasvir (VEL)/GS-9857 fixed dose combination (FDC) for 12 weeks as measured by the proportion of subjects with sustained viral response...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
7
8
9
10
11
12
13
14
15
16
Next